dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· February 20, 2026

Bitcoin 'Is Not Digital Gold,' Deutsche Bank Strategist Says Amid Price Decline

View original at finance.yahoo.com
Bitcoin 'Is Not Digital Gold,' Deutsche Bank Strategist Says Amid Price Decline Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bitcoin's price struggles are due to stalled market structure legislation in the U.S., hawkish Federal Reserve, and risk-off sentiment

    80% confidence

  • Cryptocurrency market likely to see more short-term pain with Bitcoin potentially dropping to $50,000

    80% confidence

  • Bitcoin could reach $100,000 by year-end 2025 when Kevin Warsh potentially takes office around May

    80% confidence

  • Bitcoin is an asset transitioning from purely speculative to having a real use case

    80% confidence

  • A convincing market rebound is not likely until regulations and use cases become clearer

    80% confidence

  • U.S. cryptocurrency adoption declined from 17% in July to 12% in December

    80% confidence

  • Gold outperformed Bitcoin by 65% in 2025 while Bitcoin declined by 6.5%

    80% confidence

  • Bitcoin is not a means of payment or currency and is unlikely to replace gold or fiat

    80% confidence

  • Bitcoin is not digital gold

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Bitcoin 'Is Not Digital Gold,' Deutsche Bank Strategist Says Amid Price Decline: Source | Via News | fr.via.news